Concerns Over the Drug Affordability and Patent Integrity Act
In Washington, bills with catchy titles often attract widespread support. The Drug Affordability and Patent Integrity Act, currently under review by the Senate Health, Education, Labor, and Pensions Committee, seems like a measure every American could rally behind.
But if you actually delve into the details, the implications become troubling.
This legislation would not introduce new requirements for American innovators. Instead, it could spark a surge of litigation and potentially expose sensitive medical research to foreign competitors.
Critically, it’s unlikely to reduce the cost of prescriptions.
The proposed law mandates that drug companies ensure that any data submitted to the Food and Drug Administration aligns with their disclosures to the U.S. Patent and Trademark Office. If there’s a minor error or miscommunication, the FDA might block the approval of a new drug. Imagine patients waiting for cancer treatments because of bureaucratic red tape between two federal agencies.
Proponents argue that this law would curb the misuse of the patent system.
However, existing laws already address that issue. Courts can reject patents obtained through deceit, and federal regulators have substantial authority to penalize companies that mislead the FDA.
Does this bill actually solve any pressing problem?
To make matters worse, it interferes with the effective operation of two agencies that function well separately. The FDA assesses a drug’s safety and efficacy, while the patent office evaluates the patentability of inventions. Mixing these roles doesn’t enhance the process.
This shift would empower competitors and trial lawyers to exploit the system. It could entangle legitimate patents in years of technical disputes unrelated to drug efficacy. Every dollar spent on legal battles detracts from funding for research and development.
We also need to consider national security implications.
China’s government has a stated goal to dominate the biotechnology sector, and pilfering American research plays a critical role in that strategy. Chinese hackers have targeted U.S. pharmaceutical firms for years.
If the Chinese Communist Party gains access to the files of American researchers, there’s no need for cunning tactics.
This legislation would facilitate such breaches. Pharmaceutical companies already disclose substantial amounts of confidential research to federal authorities. The new bill would increase required disclosures, extending to additional agencies and generating more applications—each becoming a potential target. At a time when China seeks to exploit American innovations, Congress would be making it even easier for them. It almost feels like this bill was crafted with malicious intent.
And all of this seems unnecessary, especially since President Trump is actively working to lower drug prices.
His initiative, TrumpRx, aims to deliver medications to American patients at prices that are often lower than those in Europe. The administration is confronting pharmacy benefit managers who inflate costs for consumers. Moreover, after years of taking advantage of American innovation, wealthy European nations are finally paying a fair price for U.S. medications, largely due to the president’s trade negotiations. All this progress has occurred without altering the patent system that fuels medical advancements.
This is the path Congress should pursue: enhancing competition, increasing transparency, and reducing the role of intermediaries that inflate drug prices. Measures like the Pharmaceutical Affordability Act and Patent Integrity Act would only create bureaucratic hurdles and unnecessary legal conflicts, giving Beijing a competitive edge.
The United States is a leader in creating new medicines because we reward those who take significant risks to heal diseases. Members of the HELP Committee ought to turn down this misdirected bill and focus on reforms that prioritize American patients.
